DualityBio’s DUPAC payload platform gains validation through a global ADC collaboration with Genentech, potentially accelerating next‑generation cancer therapeutics
Executive summary: DualityBio entered a global collaboration and license agreement with Genentech to develop next‑generation ADCs based on DualityBio’s DUPAC payload platform. The agreement validates DualityBio’s proprietary technology and provides Genentech with a new payload option to expand its oncology pipeline, potentially accelerating cancer drug development.
Who is involved: DualityBio (biotechnology firm) and Genentech (Roche subsidiary).
Likely next: Genentech will lead IND‑enabling studies and subsequent clinical trials, while DualityBio may receive milestone payments and royalties upon achievement of predefined development milestones.
DualityBio announced a global collaboration and license agreement with Genentech to co‑develop antibody‑drug conjugates using its proprietary DUPAC platform. Under the deal, Genentech will assume responsibility for later‑stage clinical development and worldwide commercialization of the ADCs, while DualityBio retains early‑stage development rights. The partnership underscores growing interest in novel payload technologies within the oncology sector and may trigger milestone payments and royalties for DualityBio as development progresses.
Timeline
- — DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform (PR Newswire)
Key entities
Sources
Open the full interactive case file on Beyond →